Objective: To evaluate the stability of cabazitaxel diluted in 0.9% sodium chloride (NS) and stored in glass. Methods: A reverse-phase stability-indicating liquid chromatographic method was developed and validated before the study. The commercially available product was prepared according to the manufacturer's instructions, and further diluted in NS to obtain concentrations of 0.120 mg/mL and 0.240 mg/mL cabazitaxel and stored in glass under refrigeration and at 25ºC, all of them protected from light. The concentration of cabazitaxel was evaluated over a period of 21 days. Results: Physical stability: The visual inspection of the stored samples to 25ºC (0.120 mg/mL and 0.240 mg/mL) indicated appearance of a white precipitate in both cases on the day 2 of study. In the case of the refrigerated samples, a similar precipitate appears on the day 6 of the study for the 0.240 mg/mL concentration and on the day 21 for 0.120 mg/mL concentration. Chemical stability: The samples that stay physically stable have been evaluated by HPLC method obtaining in all determinations a remaining percentage >95%. Solutions of cabazitaxel were subjected to a forced degradation analysis. Conclusion: Solutions of cabazitaxel 0.120 mg/mL prepared in NS and stored in glass retained more than 95% of the initial drug concentration when stored for one day at 25ºC and for twenty days at 4ºC. Solutions of cabazitaxel 0.240 mg/mL prepared in the same conditions retained more than 95% of the initial drug concentration when stored for one day at 25ºC and for two days at 4ºC.

With the aim of controlling various symptoms, possible to use mixtures of different drugs within infusion devices. This should take into account the compatibility of the mixture. Factors influence the compatibility and stability of the mixtures are: drug type, concentration, solvent, temperature and light. When evaluating the compatibility of the mixtures for infusion for subcutaneous via is important to consider infusion devices used and the conditions of light and temperature should simulate as far as possible the conditions in practice assistance. There are diverse studies that analyze the compatibility of drug mixtures, but there are still many possible combinations of drugs for which evidence is not available. The objective of this work is to study the compatibility and stability of several mixtures of haloperidol and morphine that can be used in solution for subcutaneous infusion.

Objectives: In order to avoid separate injections, admixtures of drugs are frequently used in palliative care settings. There are different factors that can influence the compatibility and stability of the mixture: drug type, concentration, solvent, container, temperature and light. There are some mixtures of drugs with proven stability, but there is lack of evidence about the stability and compatibility of the combination of morphine and furosemide. The purpose is to evaluate the compatibility and stability of two admixtures of morphine and furosemide at two different temperatures (25ºC and 37ºC). The concentrations of the admixtures are: 3.0 mg/mL-2.0 mg/mL; 1.0 mg/mL-0.6 mg/mL; in NaCl 0.9% stored in elastomeric infusors protected from light. Methods: The samples were prepared and diluted in NaCl 0.9% in elastomeric infusor in triplicate to obtain four different conditions of concentration and/or temperature of storage (concentration: 3.0 mg/mL-2.0 mg/mL, 1.0 mg/mL-0.6 mg/mL of morphine and furosemide respectively; temperature of storage 25ºC and 37ºC). The concentration of each constituent drug into different mixtures was periodically determined using a HPLC-UV method. The drugs were chromatographed on a C 18 reverse phase column; the mobile phase was acetonitrile-water 40:60 (v/v); flow rate 1.5 mL/min. Morphine and furosemide concentrations were determined at 235 nm by interpolation from the calibration curves prepared at (0,1,2,3,7,8,9,10, 14, 15) days from the standards. Statgraphics centurion XVI program has been used to data treatment. Results: The stability of the admixtures diluted in NaCl 0.9% are as follow: morphine-furosemide (3.0 mg/mL-2.0 mg/mL) is stable (retained > 95% of their initial concentration) eight days at 25ºC and two day at 37ºC; (1.0 mg/mL-0.6 mg/mL) is stable thirty days at 25ºC and two day at 37ºC. Conclusion: The admixture of morphine and furosemide in NaCl 0.9% in elastomeric infusor can be safely used in palliative care for at least two days. Concentrations of the admixture can be prepared in advance and stored at room temperature, but the infusion cannot be longer than two days.